

Fourth Global Summit on PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

October 3-5, 2019
Boston, MA

THURSDAY, OCTOBER 3, 2019

1:00 pm WELCOME AND INTRODUCTION

Faina Shtern, MD, President and CEO, AdMeTech Foundation

1:15 pm SESSION I. LEADERS OF ACADEMIA AND INDUSTRY ON ACCELERATING INNOVATION AND ITS ADOPTION IN PRECISION ONCOLOGY FOR PROSTATE CANCER: Challenges and Solutions

Moderators:

Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme

Richard Frank, Chief Medical Officer, Siemens Healthineers and Participant, US Vice President Joseph Biden's Cancer Moonshot Program

Stephen Zappala, MD, Clinical Associate, Department of Urology, Massachusetts General Hospital, Harvard Medical School

1:20 pm Keynote Address: State of the Art and Emerging Directions in Screening - Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center; and Member, Prostate Cancer Early Detection Panel, National Comprehensive Cancer Network (NCCN)

1:35 pm Q & A

1:40 pm *Liquid Biomarkers, Genetic and Phenotypic Cancer Profiling: Validation and Implementation*

1:40 pm Keynote Address: Liquid Biomarkers - E. David Crawford, MD, Clinical Professor of Urology, University of California, San Diego; Chairman, Prostate Conditions Education Council; and Editor in Chief, Grand Rounds in Urology

1:55 pm Q & A

2:00 pm Genetic Cancer Profiling: Mohammad Minhaj Siddiqui, MD, FACS, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System; Chief of Urology, Baltimore VA Medical Center; and Participant, US Vice President Joseph Biden's Cancer Moonshot Program

2:12 pm Q & A

2:15 pm Phenotypic Cancer Profiling: David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Medical Director for Associated Medical Professionals

2:27 pm Q & A

2:30 pm *Industry Leadership Panel*

2:30 pm Benjamin Solomon, MD, Managing Partner, GeneDx

2:35 pm Brad Walsh, PhD, CEO, Minomic International, Australia

2:40 pm Q & A

2:50 pm *Diagnostic Imaging, Targeted Biopsy and Focal Treatment*

2:50 pm High Resolution Micro-Ultrasound: E. David Crawford, MD

3:02 pm Q & A

3:05 pm Multi-Parametric MRI: Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI

3:17 pm Q & A

3:20 pm COFFEE BREAK

3:50 pm Molecular Imaging: Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany

4:02 pm Q & A

4:05 pm Image-Guided Biopsy and Focal Treatment: Daniel Margolis, MD, Associate Professor of Radiology and Director, Prostate MRI and Abdominal Imaging, Weill Cornell Medicine

4:17 pm Q & A

4:20 pm *Industry Leadership Panel*

4:20 pm Keynote Address: Robert Cascella, Chief Business Leader, Precision Diagnosis, and Executive Vice President, Royal Philips (TBC)

Molecular Imaging

4:35 pm Huw Jones, Vice President, Commercial, Progenics

4:45 pm Karen Linder, PhD, Associate Director, Clinical Science and Medical Affairs, Blue Earth Diagnostics

4:50 pm Q & A

Ultrasound and MRI

5:00 pm Brian Wodlinger, PhD, Director, Research and Clinical Projects, Canada

5:05 pm Heinrich von Busch, PhD, Product Owner, Artificial Intelligence for Oncology Imaging, Siemens Healthineers, Germany

5:15 pm Joseph Habovick, Chief Commercial Officer, DxTx Medical

5:20 pm Q & A

Targeted Biopsy and Treatment

5:25 pm Mathieu Burtnyk, PhD, VP for Clinical Affairs, Profound Medical, Canada

5:30 pm David Jorden, CEO, Nanospectra Bioscience

5:35 pm Antoine Leroy, PhD, CEO, Koelis, France

5:40 pm Q & A

5:45 pm *Precision Treatment*

5:45 pm Low-Risk to Intermediate-Risk Prostate Cancer: Michael Zelefsky, MD, Vice Chair, Department of Radiation Oncology, Clinical Research; and Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center

5:57 pm Q & A

High-Risk Prostate Cancer

6:00 pm Radiation Oncology: Mack Roach III, MD, Professor of Radiation Oncology and Urology, UCSF; and Member, NCCN Prostate Cancer Treatment Panel

6:12 pm Q & A

6:15 pm Keynote Address: The Future and Impact of PSMA-Targeted Radiotherapeutics - Neil H. Bander, MD, Bernard and Josephine Chaus Professor of Urologic Oncology, Weill Cornell Medicine

6:27 pm Q & A

6:30 pm Medical Oncology: David M. Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine

6:42 pm Q & A

6:45 pm *Industry Leadership Panel*

6:45 pm Perspective from Janssen and JNJ: Molecular Imaging in Prostate Cancer Drug Development: Chaitanya Divgi, MD, CEO, Divgi Consulting and Former Vice Chair, Radiology Research, Columbia University

6:50 pm Perspective from Varian Medical Systems: Brian Young, National Calypso Specialist

6:55 pm General Discussion

7:30 pm WELCOME DINNER RECEPTION, EXHIBIT TOURS AND POSTER SESSION

FRIDAY, OCTOBER 4, 2019

8:00 am SESSION II. PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: Screening and Clinical Evaluation of Men with Clinical Suspicion

Moderators:

Richard Babayan, MD, Professor and Emeritus Chairman, Department of Urology, Boston University School of Medicine and Boston Medical Center

Jim C. Hu, MD, MPH, Ronald P. Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medical College, Cornell University; and Attending Urologist, New York-Presbyterian Hospital

Masoom Haider, MD

8:05 am State of the Art in "Smart" Prostate Cancer Screening: Defining the Need for Precision Diagnostics - Sigrid V. Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center

8:17 am Q & A

8:20 am *Current and Emerging Fluid-Based Molecular Diagnostics for Improving Risk Assessment and Selection of Patients for Biopsy* - Kelvin A. Moses, MD, PhD, Associate Professor of Urology; Director, Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center; and Member, NCCN Prostate Cancer Early Detection Guidelines Panel

8:32 am Q & A

8:35 am *Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for Biopsy*

8:35 am *Real-Time High-Resolution Micro-Ultrasound*

8:35 am *Radiology Perspective*: Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada

8:47 am *Comments on Urologic Perspective*: Eric A. Klein, MD, Andrew C. Novick Distinguished Chair, Glickman Urological and Kidney Institute, and Professor of Surgery, Lerner College of Medicine, Cleveland Clinic

9:00 am Q & A

9:05 am *Contrast-Enhanced Ultrasound*: Ethan J. Halpern, MD, Professor; Vice Chair for Research, Department of Radiology; Co-Director, Prostate Diagnostic Center; and Director, Cardiac CT, Jefferson University Hospital

9:17 am Q & A

9:20 am *Multi-Parametric Magnetic Resonance Imaging*

9:20 am *PI-RADS For Risk Assessment in Biopsy Naive Men & American College of Radiology Programs in mpMRI Standardization*: Jeffrey Weinreb, MD, Professor, Department of Diagnostic Radiology and Biomedical Imaging, Yale School of Medicine; and Past Co-Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization

9:32 am *Artificial Intelligence-Based Automated Reading*: Liang Wang, MD, PhD, Professor and Vice Chair for Clinical Affairs, Director of Abdominal and Pelvic Imaging, Radiology Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

9:44 am Q & A

9:50 am *Review of the Role of MRI-Targeted Biopsy vs. Systematic Biopsy*: Mukesh Harisinghani, MD, Professor and Director of Abdominal MRI, Massachusetts General Hospital, Harvard Medical School

10:02 am Q & A

10:05 am *Molecular and Multi-Modality Imaging*: Wolfgang Weber, MD

10:17 am Q & A

10:20 am **COFFEE BREAK & EXHIBIT TOURS**

10:45 am *NCCN Guidelines for Early Detection of Prostate Cancer 2019*: Preston C. Sprenkle, MD, Associate Professor of Surgery; Director, Urology Research Fellowship; and Director, Urologic Oncology Clinical Fellowship Program, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel

10:57 am Q & A

11:00 am *Integrated Multi-Modality Diagnostic Evaluation*: Sanoj Punnen, MD, Co-Chair of Genitourinary Site Disease Group, Associate Professor, Department of Urology, University of Miami, Miller School of Medicine

11:12 am Q & A

11:15 am **Panel Discussion: Emerging Best Practices and Research Priorities** (Moderators & Speakers)

11:45 am **LUNCH SYMPOSIUM - SPONSORED BY ASTELLAS AND PFIZER**

Featured Presentation: Anthony Luongo, MD, Assistant Professor of Urology, Tufts Medical Center, Tufts University School of Medicine

12:05 pm Q & A

12:15 pm **LUNCH BREAK, EXHIBIT TOURS AND POSTER SESSION**

1:15 pm **SESSION III. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED, RECURRENT AND OLIGOMETASTATIC PROSTATE CANCER**

Moderators:

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, University of California, San Francisco

Jason Efstathiou, MD, D. Phil, Director, Genitourinary Service, Department of Radiation Oncology; and Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic and Professor of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School

Adam Kibel, MD, Elliott Carr Cutler Professor of Surgery, Harvard Medical School; and Chief of Urology, Brigham and Women's Hospital and Dana-Farber Cancer Institute

Allan Pollack, MD, PhD, Professor and Chair, Radiation Oncology, University of Miami Miller School of Medicine; Interim Deputy Director, Sylvester Comprehensive Care Center; and Service Chief, Radiation Oncology, Jackson Memorial Hospital

1:15 pm *Keynote Address: Genetic Cancer Profiling* - Eric Klein, MD

1:30 pm Q & A

1:33 pm *In Vivo Imaging: Current Clinical Utility of mpMRI and Multi-Modality Imaging* - Jelle Barentsz, MD, PhD, Chair and Professor of Radiology, Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands

1:45 pm Q & A

1:48 pm *Non-Invasive Molecular Imaging and its Impact on Management of Initial Diagnosis and Suspected Recurrence*

1:48 pm *Suspected Recurrence (18F-fluciclovine)*: Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center; and Member, NCCN Cancer Early Detection Panel

2:00 pm Q & A

2:03 pm *Initial Diagnosis and Suspected Recurrence (PSMA)*: Steven Rowe, MD, PhD, Assistant Professor of Radiology, Johns Hopkins University School of Medicine

2:15 pm Q & A

2:18 pm *Considerations for the Clinical Impact of Next Generation Imaging on Prostate Cancer Care*: Ashley Ross, MD, PhD, Urology Specialists, Texas Oncology; Associate Chair, US Oncology GU Research Committee; and Executive Medical Director, Mary Crowley Cancer Research Center

2:30 pm Q & A

2:33 pm *Intra-Operative Molecular Imaging*: Wolfgang Weber, MD

2:45 pm Q & A

2:48 pm *Precision Imaging and its Emerging Impact on Treatment*

2:48 pm *Radiation Oncology Perspective on Treatment Planning of Localized Disease*: Ashesh B. Jani, MD, MSEE, Professor, Department of Radiation Oncology, Emory University

3:00 pm *Urology Perspective on Treatment of Localized Disease*: Mohammad Minhaj Siddiqui, MD

3:12 pm Q & A

3:16 pm *Radiation Oncology Perspective on Treatment of Oligometastatic Disease*: Jason Efstathiou, MD, D. Phil.

3:28 pm Q & A

3:30 am **COFFEE BREAK**

4:00 pm *Radiomics and Machine Learning*: Masoom Haider, MD

4:12 pm Q & A

4:15 pm *Pathologic Assessment and Patient Outcomes*

4:15 pm *Pathology Perspective*: Thomas Wheeler, MD, Senior Vice Chair for Faculty Group Pathology and Professor of Pathology, Baylor College of Medicine

4:27 pm Q & A

4:30 pm *Restricted Mean Survival Times (RMST) as the Novel Measure of Patient Outcomes*: Jennifer Rider, ScD, MPH, Assistant Professor, Department of Epidemiology, Boston University School of Public Health

4:42 pm Q & A

4:45 pm *Radiogenomics: Emerging and Future Impact on Treatment Selection and Monitoring*

4:45 pm *Active Surveillance*: Sanoj Punnen, MD

4:57 pm Q & A

5:00 pm *Focal Treatment*: Fiona Fennessy, MD, BCh, PhD, Associate Professor of Radiology, Harvard Medical School; Faculty Radiologist, Brigham and Women's Hospital; Program Director, Cancer Imaging Fellowship Program, and Institute Physician, Dana-Farber Cancer Institute

5:12 pm Q & A

5:15 pm *Whole Gland Treatment*

5:15 pm *Radiation Oncology Perspective*: Alan Pollack, MD, PhD,

5:27 pm Q & A

5:30 pm *Urology Perspective:* Adam S. Feldman, MD, MPH, Assistant Professor of Surgery, Director of Combined Harvard Urology Oncology Fellowship, and Director of Research, Massachusetts General Hospital, Harvard Medical School

5:42 pm Q & A

5:45 pm **UCSF Consensus on Prostate Cancer Biomarkers:** Matthew R. Cooperberg, MD, MPH

5:57 pm Q & A

6:00 pm **Advances in Radiation Treatment: Randomized Phase III Clinical Trial Comparing Patient Outcomes of IMRT vs. Proton Beam:** Jason Efstathiou, MD, D. Phil.

6:12 pm Q & A

6:15 pm **Panel on Diagnostic Evaluation of Men with Proven Localized Prostate Cancer and its Impact on Treatment Design and Monitoring:**

Quality Improvement in Prostate MRI - A National Veterans Hospital Initiative: Sadhna Verma, MD, Professor of Radiology, University of Cincinnati Medical Center

Multi-Parametric Nomograms: Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan-Kettering Cancer Center and Andreas Wibmer, MD, Radiologist, Memorial Sloan-Kettering Cancer Center

Image-Guided Minimally-Invasive Whole Gland Treatment: Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA

7:00 pm **DINNER SYMPOSIUM - SPONSORED BY PHILIPS**

Featured Presentation - Advances in Prostate Cancer Care Over the Past Decade and Evolution of Imaging, Fusion Biopsy, and Focal Therapy: Art Rastinehad, DO, FACOS, Associate Professor of Urology and Radiology, and Director, Focal Therapy and Interventional Urology Program, Icahn School of Medicine at Mount Sinai Health System

7:40 pm Q & A

8:00 pm **EXHIBIT TOURS AND POSTER SESSION**

SATURDAY, OCTOBER 5, 2019

8:00 am **SESSION IV. PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT**

Moderators:

Mitchell H. Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine and UMass Memorial Medical Center

Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine

8:00 am **Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes**

8:00 am *Overview:* Jurgen Fütterer, MD, PhD, Interventional Radiologist, Nijmegen Medical Center and Professor, University of Twente, the Netherlands

8:12 am Q & A

8:15 am *Current and Emerging Role of Radiogenomics:* John Feller, MD, Medical Director and Founding Partner, Desert Medical Imaging; and Associate Clinical Professor of Radiology, Loma Linda University School of Medicine

8:27 am Q & A

8:30 am *Novel Emerging Approaches to Focal Treatment:* Art Rastinehad, DO, FACOS

8:42 am Q & A

8:45 am *Surveillance After Focal Therapy of Prostate Cancer:* Abhinav Sidana, MD, Assistant Professor of Surgery and Director of Urologic Oncology, University of Cincinnati College of Medicine

8:57 am Q & A

9:00 am **Clinical Role of Focal Treatment vs. Active Surveillance and Whole Gland Rx**

9:00 am *Radiology Perspective:* Aytekin Oto, MD, MBA, Interim Chairman and Professor of Radiology and Surgery, Department of Radiology, University of Chicago

9:12 am Q & A

9:15 am *Radiation Oncology Perspective:* Daniel Y. Song, MD, Co-Director, Prostate Cancer Multidisciplinary Clinic and Associate Professor of Radiation Oncology and Molecular Radiation Sciences, Urology and Oncology, Johns Hopkins University School of Medicine

9:27 am Q & A

9:30 am *Urology Perspective:* Jim C. Hu, MD, MPH

9:42 am Q & A

9:45 am **COFFEE BREAK**

10:15 am **SESSION V. POPULATION OF MEN WITH ADVANCED PROSTATE CANCER**

Moderators: David Nanus, MD and Christopher Sweeney, MD, MBBS, Medical Oncologist, Dana Farber Cancer Institute; and Professor of Medicine, Harvard Medical School

10:15 am **Overview of Treatment for Advanced Prostate Cancer, including Metastatic Disease**

10:15 am *Standard Treatment:* David Nanus, MD

10:27 am Q & A

10:30 am *Novel Treatment:* Christopher Sweeney, MD, MBBSI

10:42 am Q & A

10:45 am **Featured Presentation - Current and Future Role of Radium 223 in Prostate Cancer Care:** Philip Koo, MD, Division Chief, Diagnostic Imaging, Banner MD Anderson Cancer Center

11:00 am Q & A

11:03 am **Liquid Biomarkers - Including Circulating Tumor Cells and Germline Testing:** David Nanus, MD

11:15 am Q & A

11:18 am **Special Presentation - Exosomal Liquid Biopsy in Prostate Cancer - Role in Prostate Biopsy Decision-Making:** Judd Moul, MD, James H. Semans, M.D. Professor of Urologic Surgery, Professor of Surgery and Anesthesiology, School of Medicine, Duke University

11:33 am Q & A

11:35 am **Molecular and Multi-Modality Imaging**

11:35 am *Prostate Specific PET Imaging Overview: Next Step in Defining Clinical Utility* Christopher Sweeney, MD, MBBS

11:47 am Q & A

11:50 am *PSMA-11 PET: Atypical paths to FDA approval and Academic NDAs -* Thomas Hope, MD, Assistant Professor in Residence, Abdominal Imaging and Nuclear Medicine, Department of Radiology, UCSF

12:02 am Q & A

12:05 pm *Theranostics of Prostate Cancer*

12:05 pm *Current State of the Art:* Wolfgang Weber, MD

12:17 pm *Vision for the Future:* Philip Koo, MD

12:29 am Q & A

12:35 pm **Panel Discussion (Moderators and Speakers)**

1:00 pm **LUNCH SYMPOSIUM - SPONSORED BY PROGENICS**

Featured Presentation - Current Landscape of Diagnostic Molecular Imaging of Prostate Cancer in the US: Andrei H. Iagaru, MD, FACNM, Professor of Radiology and Chief, Nuclear Medicine and Molecular Imaging Division; Director, Nuclear Medicine Residency Program; and Co-Director, PET-MRI Research Program, Stanford University

1:20 pm Q & A

1:30 pm **LUNCH BREAK: REFRESHMENTS, EXHIBIT TOURS AND POSTER SESSION**

2:15 pm **Bioinformatics for a Multi-Modality Approach to Precision Diagnosis and Treatment, Including Radiogenomics:** Paul Boutros, MD, PhD, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA

2:27 pm Q & A

2:30 pm **SESSION VI. SUMMARY PANEL DISCUSSION ON SUMMIT HIGHLIGHTS: Most Promising Clinical and Research Trends in Precision Screening, Diagnosis and Treatment**

Moderators: Matthew R. Cooperberg, MD, MPH and Faina Shtern, MD

Panelists: Jelle Barentsz, MD, PhD; Masoom Haider, MD; Jim C. Hu, MD, MPH, David Nanus, MD; Alan Pollack, MD, PhD; Mohammad Minhaj Siddiqui, MD; Christopher Sweeney, MD, MBBS; Wolfgang Weber, MD.

3:30 pm **REFRESHMENTS, EXHIBIT TOURS, AND POSTER SESSION**

5:30 pm **ADJOURN**

Made possible by the Commonwealth of Massachusetts and the Philanthropic Contribution of Miriam and David Donoho

SPONSORS AND EXHIBITORS

GOLD

PHILIPS

SILVER



BRONZE II



BRONZE



EXHIBITORS



ACKNOWLEDGMENTS



Media Partner



Supported by an educational grant from AstraZeneca

AdMeTech FOUNDATION the manogram project precision prostate care for every man In Memory of Paul Leighton Donoho and Ferenc Jolesz

Save the Date
Fifth Global Summit on
PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

October 2-4, 2020
Boston, MA